Immunotherapy including immune checkpoint inhibitors (ICIs) has become the backbone of
treatment for most lung cancers with advanced or metastatic disease. In addition, they have …

Lung cancer has the highest mortality rate among all cancer types, resulting in over 1.8
million deaths annually. Immunotherapy utilizing immune checkpoint inhibitors (ICIs) has …

Purpose: We sought to identify features of patients with advanced non–small cell lung
cancer (NSCLC) who achieve long-term response (LTR) to immune checkpoint inhibitors …

Background A prior study found that, among advanced non-small cell lung cancer
(aNSCLC) patients with PD-L1 expression 50% to 100% receiving immunotherapy as …

Background It has been reported that smoking history as a predictor of immunotherapy
efficacy in patients with advanced lung cancer, however, the underlying mechanisms of this …

Immune checkpoint inhibitors (ICIs), especially anti-PD-1/PD-L1 antibodies, have made
dramatic progress in treatment of lung cancer, especially for non-oncogene driven patients …

Lung cancer is responsible for 1.8 million annual deaths. Non-small cell lung cancers
(NSCLC) represent 85% of lung cancer tumors. While surgery is an effective early-stage …

Background/Aim: Programmed death ligand-1 (PD-L1) expression is known to be a
predictive biomarker for response to immunotherapy in non-small cell lung cancer (NSCLC) …

Abstract Aims As PD-L1 expression has been proposed as one of the cancer biomarkers for
non-small cell lung cancer (NSCLC), the predictive value of tumour proportional score (TPS) …

Aims To investigate the predictive value of baseline C-reactive protein (CRP) levels on the
efficacy of chemotherapy plus immune checkpoint inhibitors (ICI) in patients with advanced …